| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.36 | 0.2 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |